Pagcantratinib is in phase IIb clinical trials for treatment of pruritus associated with psoriasis.220 Pegcantratinib has also been in a Phase II combination study with calcipotriene (vitamin D receptor agonist) to treat both pruritus and psoriasis.221. Here, VDR is linked to psoriasis.